Stem Cell Therapy Market Size, Share & Trends Analysis By Type, By Cell source, By Therapeutic Application, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Global Stem Cell Therapy Market projected to be worth USD 700.19 million by 2030.
According to SPER Market Research, the Stem Cell Therapy Market estimated to reach USD 700.19 million by 2030 with a CAGR of 15.8%. The fuels for the escalation of the Stem Cell Therapy Market are; increasing stem cell research and GMP-certified facilities to manufacture stem cells, rising demand for induced pluripotent stem cells.
Impact of COVID-19 on the Stem Cell Therapy Market
COVID-19 outbreak has a positive impact on the Stem Cell Therapy Market.
Scope of the report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Type, By Cell Source, By Therapeutic Application, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered AlloSource, Anterogen, BioRestorative Therapies, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, CORESTEM, Holostem Terapie Avanzate S.r.l, Hope Biosciences, JCR Pharmaceuticals, Kangstem Biotech, MEDIPOST, Mesoblast, NuVasive, Orthofix, Personalized Stem Cells, PHARMICELL, Pluristem Therapeutics, Regrow Biosciences, RTI Surgical, Smith & Nephew Stempeutics Research, Under Pipeline Athersys, Takeda Pharmaceutical Company, ViaCyte
Driver: funding for stem cell research
Availability of funding for stem cell research, increasing GMP-certification approvals for cell therapy production facilities, increasing clinical trials for stem cell based-therapies; are the key driver for the expansion of this market.
Restraints:
Ethical concerns related to embryonic stem cells, costly cell-based research; are the restraint to the market growth.
Opportunity:
Growing demand for cell & gene therapies, the emergence of induced pluripotent stem cells alternative to embryonic stem cells; provide huge opportunities for the players in the market.
Global Stem Cell Therapy Market, By Type:
Based on the Type, Global Stem Cell Therapy Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
Global Stem Cell Therapy Market, By Cell Source:
Based on the Cell Source, Global Stem Cell Therapy Market is segmented as; Adipose tissue-derived MSCs (mesenchymal stem cells), Bone marrow-derived MSCs, Placental/umbilical cord-derived MSCs, and Other Cell Sources.
Global Stem Cell Therapy Market, By Therapeutic Application:
Based on the Therapeutic Application, Global Stem Cell Therapy Market is segmented as; Cardiovascular Diseases, Inflammatory & Autoimmune Diseases, Musculoskeletal Disorders, Neurological Disorders, Surgeries, Wounds & Injuries, Other Therapeutic Applications.
Global Stem Cell Therapy Market, By Region:
North America owns the biggest share of this Stem Cell Therapy Market; this is due to growing public-private partnership funding, research grants to develop safe & effective stem cell therapy products, and increasing figure of clinical trials.
According to SPER Market Research, the Stem Cell Therapy Market estimated to reach USD 700.19 million by 2030 with a CAGR of 15.8%. The fuels for the escalation of the Stem Cell Therapy Market are; increasing stem cell research and GMP-certified facilities to manufacture stem cells, rising demand for induced pluripotent stem cells.
Impact of COVID-19 on the Stem Cell Therapy Market
COVID-19 outbreak has a positive impact on the Stem Cell Therapy Market.
Scope of the report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Type, By Cell Source, By Therapeutic Application, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered AlloSource, Anterogen, BioRestorative Therapies, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, CORESTEM, Holostem Terapie Avanzate S.r.l, Hope Biosciences, JCR Pharmaceuticals, Kangstem Biotech, MEDIPOST, Mesoblast, NuVasive, Orthofix, Personalized Stem Cells, PHARMICELL, Pluristem Therapeutics, Regrow Biosciences, RTI Surgical, Smith & Nephew Stempeutics Research, Under Pipeline Athersys, Takeda Pharmaceutical Company, ViaCyte
Driver: funding for stem cell research
Availability of funding for stem cell research, increasing GMP-certification approvals for cell therapy production facilities, increasing clinical trials for stem cell based-therapies; are the key driver for the expansion of this market.
Restraints:
Ethical concerns related to embryonic stem cells, costly cell-based research; are the restraint to the market growth.
Opportunity:
Growing demand for cell & gene therapies, the emergence of induced pluripotent stem cells alternative to embryonic stem cells; provide huge opportunities for the players in the market.
Global Stem Cell Therapy Market, By Type:
Based on the Type, Global Stem Cell Therapy Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
Global Stem Cell Therapy Market, By Cell Source:
Based on the Cell Source, Global Stem Cell Therapy Market is segmented as; Adipose tissue-derived MSCs (mesenchymal stem cells), Bone marrow-derived MSCs, Placental/umbilical cord-derived MSCs, and Other Cell Sources.
Global Stem Cell Therapy Market, By Therapeutic Application:
Based on the Therapeutic Application, Global Stem Cell Therapy Market is segmented as; Cardiovascular Diseases, Inflammatory & Autoimmune Diseases, Musculoskeletal Disorders, Neurological Disorders, Surgeries, Wounds & Injuries, Other Therapeutic Applications.
Global Stem Cell Therapy Market, By Region:
North America owns the biggest share of this Stem Cell Therapy Market; this is due to growing public-private partnership funding, research grants to develop safe & effective stem cell therapy products, and increasing figure of clinical trials.
1. INTRODUCTION
1.1. Scope of the report
1.2. Market segment analysis
2. RESEARCH METHODOLOGY
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Stem Cell Therapy Market
5. MARKET VARIABLES AND OUTLOOK
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2019-2030 (USD MILLION)
6.1. Allogeneic Stem Cell Therapy
6.2. Autologous Stem Cell Therapy
7. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2030 (USD MILLION)
7.1. Adipose tissue-derived MSCs (mesenchymal stem cells),
7.2. Bone marrow-derived MSCs,
7.3. Placental/umbilical cord-derived MSCs, and
7.4. Other Cell Sources
8. GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2030 (USD MILLION)
8.1. Cardiovascular Diseases
8.2. Inflammatory & Autoimmune Diseases
8.3. Musculoskeletal Disorders
8.4. Neurological Disorders,
8.5. Other Therapeutic Applications
8.6. Surgeries,
8.7. Wounds & Injuries
9. GLOBAL STEM CELL THERAPY MARKET, BY REGION, 2019-2030 (USD MILLION)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. COMPANY PROFILES
10.1. AlloSource
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Anterogen
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. BioRestorative Therapies
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. BrainStorm Cell Therapeutics
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Cellular Biomedicine Group
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. CORESTEM
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Holostem Terapie Avanzate S.r.l
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Hope Biosciences
10.7.5. Company details
10.7.6. Financial outlook
10.7.7. Product summary
10.7.8. Recent developments
10.9. JCR Pharmaceuticals
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.10. Kangstem Biotech
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. MEDIPOST
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. Mesoblast
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. NuVasive
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Orthofix
10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Personalized Stem Cells
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. PHARMICELL
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments
10.17. Pluristem Therapeutics
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments
10.18. Regrow Biosciences
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments
10.19. RTI Surgical
10.18.5. Company details
10.18.6. Financial outlook
10.18.7. Product summary
10.18.8. Recent developments
10.20. Smith & Nephew
10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments
10.21. Stempeutics Research
10.21.1. Company details
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments
10.22. Under Pipeline Athersys
10.22.1. Company details
10.22.2. Financial outlook
10.22.3. Product summary
10.22.4. Recent developments
10.23. Takeda Pharmaceutical Company
10.23.1. Company details
10.23.2. Financial outlook
10.23.3. Product summary
10.23.4. Recent developments
10.24. ViaCyte
10.24.1. Company details
10.24.2. Financial outlook
10.24.3. Product summary
10.24.4. Recent developments
1.1. Scope of the report
1.2. Market segment analysis
2. RESEARCH METHODOLOGY
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Stem Cell Therapy Market
5. MARKET VARIABLES AND OUTLOOK
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. GLOBAL STEM CELL THERAPY MARKET, BY TYPE, 2019-2030 (USD MILLION)
6.1. Allogeneic Stem Cell Therapy
6.2. Autologous Stem Cell Therapy
7. GLOBAL STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019-2030 (USD MILLION)
7.1. Adipose tissue-derived MSCs (mesenchymal stem cells),
7.2. Bone marrow-derived MSCs,
7.3. Placental/umbilical cord-derived MSCs, and
7.4. Other Cell Sources
8. GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019-2030 (USD MILLION)
8.1. Cardiovascular Diseases
8.2. Inflammatory & Autoimmune Diseases
8.3. Musculoskeletal Disorders
8.4. Neurological Disorders,
8.5. Other Therapeutic Applications
8.6. Surgeries,
8.7. Wounds & Injuries
9. GLOBAL STEM CELL THERAPY MARKET, BY REGION, 2019-2030 (USD MILLION)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. COMPANY PROFILES
10.1. AlloSource
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Anterogen
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. BioRestorative Therapies
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. BrainStorm Cell Therapeutics
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Cellular Biomedicine Group
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. CORESTEM
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Holostem Terapie Avanzate S.r.l
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Hope Biosciences
10.7.5. Company details
10.7.6. Financial outlook
10.7.7. Product summary
10.7.8. Recent developments
10.9. JCR Pharmaceuticals
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.10. Kangstem Biotech
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. MEDIPOST
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. Mesoblast
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. NuVasive
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Orthofix
10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Personalized Stem Cells
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. PHARMICELL
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments
10.17. Pluristem Therapeutics
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments
10.18. Regrow Biosciences
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments
10.19. RTI Surgical
10.18.5. Company details
10.18.6. Financial outlook
10.18.7. Product summary
10.18.8. Recent developments
10.20. Smith & Nephew
10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments
10.21. Stempeutics Research
10.21.1. Company details
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments
10.22. Under Pipeline Athersys
10.22.1. Company details
10.22.2. Financial outlook
10.22.3. Product summary
10.22.4. Recent developments
10.23. Takeda Pharmaceutical Company
10.23.1. Company details
10.23.2. Financial outlook
10.23.3. Product summary
10.23.4. Recent developments
10.24. ViaCyte
10.24.1. Company details
10.24.2. Financial outlook
10.24.3. Product summary
10.24.4. Recent developments
